Keyword: Teva Pharmaceutical Industries
BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
Novartis Oncology head Bruno Strigini retires, Amneal poaches Allergan's Robert Stewart, plus more hirings, firings and retirings across the industry.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.
Teva's restructuring plan will include the closure or divestiture of R&D facilities, as well as a "thorough review" of its R&D programs.
Teva Pharmaceutical will reveal a restructuring plan on Thursday which includes shutting a research and development center.
Active Biotech and Teva’s laquinimod—once billed as a successor to MS blockbuster Copaxone—has hit yet another snag after failing a phase 2 trial.
CSO Hayden will leave as Teva restructures, Bayer R&D reorg sees Moeller in and Busch out for Shire, Shire and Biogen get experienced CFOs.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.
BioSensics picked up more than $2.5 million in an NIH grant to develop a remote monitoring device for Huntington disease.